Search research articles
Contact Us
Filters
Showing results (121-130 of 128) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 128 results.
Biorxiv : the Preprint Server for Biology
|
July 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub> degradation to overcome cancer chemoresistance
Xingping Qin, Adam Presser, Lissah Johnson, et al.
The Lancet. Oncology
|
March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 8, 2019
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 5, 2021
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Joyce Liu, Andrew Berchuck, Floor J Backes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, et al.
Journal of Medicinal Chemistry
|
May 18, 2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
Summer A Baker Dockrey, Pravin Chandra, Huifen Chen, et al.
JCO Precision Oncology
|
September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 128) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 128 results.
Biorxiv : the Preprint Server for Biology
|
July 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub> degradation to overcome cancer chemoresistance
Xingping Qin, Adam Presser, Lissah Johnson, et al.
The Lancet. Oncology
|
March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 8, 2019
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 5, 2021
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Joyce Liu, Andrew Berchuck, Floor J Backes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, et al.
Journal of Medicinal Chemistry
|
May 18, 2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
Summer A Baker Dockrey, Pravin Chandra, Huifen Chen, et al.
JCO Precision Oncology
|
September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Page
of 13